Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[What are the new therapeutic strategies in metastatic colorectal cancer including biotherapies?].

La Revue de medecine interne - 1 May 2009

Tournigand C, Bengrine-Lefevre L

Abstract excerpt

Colorectal cancer remains one of the major causes of cancer death. Recent identification of new molecular targets led to the development of novel agents directed against growth factor receptors or key factors of angiogenesis. Recent phase III trials demonstrated a significant clinical benefit with bevacizumab, a VEGF inhibitor, and with EGFR-inhibitors, namely cetuximab and panitumumab. In this article we review...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Cetuximab

Share to Clinical Trials, Phase III as Topic

Share to Neovascularization, Pathologic

Share to Panitumumab

Share to Vascular Endothelial Growth Factor A

Source

Identifiers

PMID: 19231039
DOI: 10.1016/j.revmed.2008.12.015

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[What are the new therapeutic strategies in metastatic colorectal cancer including biotherapies?].PMID 19231039Read ↗

Personalizing medicine for metastatic colorectal cancer: current developments.Semantic proximity Read ↗

[Targeted therapies for metastatic colorectal cancer].Semantic proximity Read ↗

Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.Semantic proximity Read ↗

Current perspectives on the treatment of BRAF mutated colorectal carcinoma.Semantic proximity Read ↗

[Recent Advances in Systemic Chemotherapy for Metastatic Colorectal Cancer].Semantic proximity Read ↗

BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights.Semantic proximity Read ↗

A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.Semantic proximity Read ↗

A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistanceSemantic proximity Read ↗

Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era.Semantic proximity Read ↗

A review on emerging targeted therapies for the management of metastatic colorectal cancers.Semantic proximity Read ↗

Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in ReviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.